Search

Your search keyword '"Edelman, Martin J."' showing total 14 results
Start Over Author "Edelman, Martin J." Journal clinical lung cancer
14 results on '"Edelman, Martin J."'

3. Chemotherapy Outcomes by Histologic Subtypes of Non-Small-Cell Lung Cancer: Analysis of the Southwest Oncology Group Database for Antimicrotubule-Platinum Therapy

Author

Kelly, Karen, Chansky, Kari, Mack, Philip C, Jr, Lara Primo N, Hirsch, Fred R, Franklin, Wilbur A, Wozniak, Antoinette J, Edelman, Martin J, Williamson, Stephen K, and Gandara, David R

Subjects
Chemotherapy outcomes, Histology, Lung cancer, Oncology & Carcinogenesis, Clinical Sciences, Oncology and Carcinogenesis
Published
2013

14. The Potential Role of Bortezomib in Combination with Chemotherapy and Radiation in Non–Small-Cell Lung Cancer

Author

Edelman, Martin J.

Abstract

The combination of chemotherapy and radiation has been validated for the treatment of locally advanced non–small-cell lung cancer (NSCLC). However, the results are still unsatisfactory, and there is a need to improve current treatment. One approach is to use new agents that have the potential to enhance the efficacy of chemotherapy, radiation therapy (RT), or both. One potential target is the ubiquitin–proteasome pathway. This pathway plays an essential role in the degradation of most short- and long-lived intracellular proteins in eukaryotic cells and therefore regulating the cell cycle, neoplastic growth, and metastasis. Bortezomib is a selective 26S proteasome inhibitor that has been approved for the treatment of multiple myeloma. Bortezomib has demonstrated in vitro chemotherapy- and RT–sensitizing properties as well as single-agent activity in lung cancer. This article will review the rationale for the use of bortezomib as part of the chemotherapy/RT strategy for the treatment of NSCLC.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results